肌醇用于腹主动脉瘤管理(IMAGEN):随机对照试验研究方案
IMAGEN是一项多中心、前瞻性、平行组、随机、双盲、安慰剂对照试验,计划纳入164例腹主动脉瘤≥30 mm的受试者,随机接受肌醇2 g每日两次或相同安慰剂治疗12个月。主要结局为CT测量的肾下腹主动脉总体积增加所估计的腹主动脉瘤增长,次要结局包括CT和超声评估的腹主动脉瘤直径、峰值壁应力与峰值壁破裂指数、血清脂质、循环腹主动脉瘤生物标志物、循环RNA及健康相关生活质量。目前尚无已知药物疗法可限制腹主动脉瘤进展,据作者所知IMAGEN将是首个评估肌醇限制腹主动脉瘤增长价值的随机试验。
要点
- 纳入腹主动脉瘤≥30 mm的受试者,随机接受肌醇2 g每日两次或相同安慰剂治疗12个月。
- 主要结局为CT测量的肾下腹主动脉总体积增加所估计的腹主动脉瘤增长。
- 目前尚无已知药物疗法可限制腹主动脉瘤进展,据作者所知IMAGEN为首个评估肌醇限制腹主动脉瘤增长价值的随机试验。
核心结论
- 目前尚无已知药物疗法可限制腹主动脉瘤进展,据作者所知IMAGEN将是首个评估肌醇限制腹主动脉瘤增长价值的随机试验。
研究设计与样本
- IMAGEN为多中心、前瞻性、平行组、随机、双盲、安慰剂对照试验,共计划纳入164例腹主动脉瘤≥30 mm的受试者。
- 受试者随机接受肌醇2 g每日两次或相同安慰剂治疗12个月。
- 所有分析将基于随机化时的意向性治疗原则,所有符合入选标准、提供书面知情同意并入选研究的患者均纳入主要分析,无论是否依从饮食分配。
关键数值与推荐
- 主要结局指标为通过计算机断层扫描测量的肾下腹主动脉总体积增加所估计的腹主动脉瘤增长。
- 次要结局指标包括通过计算机断层扫描和超声评估的腹主动脉瘤直径、腹主动脉瘤峰值壁应力和峰值壁破裂指数、血清脂质、循环腹主动脉瘤生物标志物、循环RNAs及健康相关生活质量。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: An abdominal aortic aneurysm (AAA) is a focal dilation of the abdominal aorta and is associated with a risk of fatal rupture. Experimental studies suggest that myo-inositol may exert beneficial effects on AAAs through favourable changes to biological pathways implicated in AAA pathology. The aim of the Inositol in the MAnaGemENt of abdominal aortic aneurysm (IMAGEN) trial is to assess if myo-inositol will reduce AAA growth. METHODS/DESIGN: IMAGEN is a multi-centre, prospective, parallel-group, randomised, double-blind, placebo-controlled trial. A total of 164 participants with an AAA measuring ≥ 30 mm will be randomised to either 2 g of myo-inositol or identical placebo twice daily for 12 months. The primary outcome measure will be AAA growth estimated by increase in total infrarenal aortic volume measured on computed tomographic scans. Secondary outcome measures will include AAA diameter assessed by computed tomography and ultrasound, AAA peak wall stress and peak wall rupture index, serum lipids, circulating AAA biomarkers, circulating RNAs and health-related quality of life. All analysis will be based on the intention-to-treat principle at the time of randomisation. All patients who meet the eligibility criteria, provide written informed consent and are enrolled in the study will be included in the primary analysis, regardless of adherence to dietary allocation. DISCUSSION: Currently, there is no known medical therapy to limit AAA progression. The IMAGEN trial will be the first randomised trial, to our knowledge, to assess the value of myo-inositol in limiting AAA growth. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry, ACTRN12615001209583 . Registered on 6 November 2015.
引用
- Rowbotham SE, Pinchbeck JL, Anderson G, et al. Inositol in the MAnaGemENt of abdominal aortic aneurysm (IMAGEN): study protocol for a randomised controlled trial. Trials. 2017. PMID: 29145894. doi:10.1186/s13063-017-2304-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。